GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 May 2022 05:13 PM
RNS
Director/PDMR Shareholding
12 May 2022 08:58 AM
RNS
Director/PDMR Shareholding
11 May 2022 05:17 PM
RNS
Block listing Interim Review
09 May 2022 02:53 PM
RNS
Director/PDMR Shareholding
04 May 2022 05:49 PM
RNS
Result of AGM
04 May 2022 10:00 AM
RNS
Directorate Change
03 May 2022 04:52 PM
RNS
Total Voting Rights
27 Apr 2022 07:00 AM
RNS
1st Quarter Results
26 Apr 2022 09:32 AM
RNS
Director/PDMR Shareholding
19 Apr 2022 07:00 AM
RNS
Daprodustat application accepted for review by FDA
14 Apr 2022 02:23 PM
RNS
Director/PDMR Shareholding
14 Apr 2022 02:15 PM
RNS
Director/PDMR Shareholding
14 Apr 2022 01:29 PM
RNS
Director/PDMR Shareholding
13 Apr 2022 05:11 PM
RNS
Director/PDMR Shareholding
13 Apr 2022 09:32 AM
RNS
Director/PDMR Shareholding
13 Apr 2022 07:00 AM
RNS
GSK agrees to acquire Sierra Oncology for $1.9bn
12 Apr 2022 05:10 PM
RNS
Director/PDMR Shareholding
12 Apr 2022 04:23 PM
RNS
Director/PDMR Shareholding
12 Apr 2022 04:00 PM
RNS
Director/PDMR Shareholding
12 Apr 2022 03:48 PM
RNS
Director/PDMR Shareholding
01 Apr 2022 04:03 PM
RNS
Total Voting Rights
01 Apr 2022 11:20 AM
RNS
GSK - segment and product sales reporting changes
28 Mar 2022 01:00 PM
RNS
Publication of 2022 AGM Notice
24 Mar 2022 03:22 PM
RNS
Director/PDMR Shareholding
24 Mar 2022 02:00 PM
RNS
FDA update: Cabenuva oral lead-in now optional
23 Mar 2022 05:03 PM
RNS
Director/PDMR Shareholding
23 Mar 2022 07:00 AM
RNS
Issuance of Notes
16 Mar 2022 02:40 PM
RNS
Director/PDMR Shareholding
15 Mar 2022 02:45 PM
RNS
Director/PDMR Shareholding
15 Mar 2022 10:00 AM
RNS
Appointments to Designate Haleon Board
11 Mar 2022 02:55 PM
RNS
Director/PDMR Shareholding
09 Mar 2022 01:44 PM
RNS
Director/PDMR Shareholding
08 Mar 2022 06:24 PM
RNS
GSK Annual Report 2021 on Form 20-F
04 Mar 2022 11:03 AM
RNS
GSK publishes Annual Report 2021
01 Mar 2022 02:30 PM
RNS
Total Voting Rights
01 Mar 2022 01:18 PM
RNS
Director/PDMR Shareholding
01 Mar 2022 09:55 AM
RNS
Director/PDMR Shareholding
01 Mar 2022 07:00 AM
RNS
Daprodustat application accepted for review by EMA
28 Feb 2022 11:00 AM
RNS
GSK introduces Haleon to investors
28 Feb 2022 07:00 AM
RNS
GSK RSV maternal vaccine candidate further update
24 Feb 2022 04:22 PM
RNS
Director/PDMR Shareholding
24 Feb 2022 03:12 PM
RNS
Canada Approval For Medicago GSK Covid-19 Vaccine
23 Feb 2022 02:50 PM
RNS
Director/PDMR Shareholding
22 Feb 2022 02:00 PM
RNS
GSK Consumer Healthcare to be called Haleon
22 Feb 2022 09:22 AM
RNS
Director/PDMR Shareholding
18 Feb 2022 04:30 PM
RNS
Director/PDMR Shareholding
18 Feb 2022 07:00 AM
RNS
GSK gives update on RSV maternal vaccine candidate
17 Feb 2022 04:00 PM
RNS
Director/PDMR Shareholding
17 Feb 2022 03:40 PM
RNS
Director/PDMR Shareholding
17 Feb 2022 03:20 PM
RNS
Director/PDMR Shareholding

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

UK 100

Latest directors dealings